39.00
-0.66 (-1.66%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Rapport Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -1.5 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.63 |
|
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 6.28% |
| 机构持股比例 | 105.23% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Trv Gp V, Llc | 30 Jun 2026 | 6,280,525 |
| Sofinnova Investments, Inc. | 30 Jun 2026 | 1,904,408 |
| Johnson & Johnson | 30 Jun 2026 | 1,784,517 |
| Polar Capital Holdings Plc | 30 Jun 2026 | 1,608,514 |
| Trv Gp Vi, Llc | 30 Jun 2026 | 969,218 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| CEESAY ABRAHAM | - | 46.09 | -8,210 | -378,399 |
| 累积净数量 | -8,210 | |||
| 累积净值 ($) | -378,399 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 46.09 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| CEESAY ABRAHAM | 职员 | 08 Sep 2026 | 自动卖出 (-) | 8,210 | 46.09 | 378,399 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合